Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Leukemia 3Thalassemia 2Primary Immunodeficiency Diseases 2Multiple Myeloma 2Hemoglobinopathies 2Hematologic Neoplasms 2Fanconi Anemia 2Cytopenia 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia, Aplastic 2Anemia 2Uveal Melanoma 1Recurrence 1Osteopetrosis 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

Rituximab 173Cyclophosphamide 157Vincristine 72fludarabine phosphate 71Doxorubicin 69Etoposide 68Prednisone 67Filgrastim 58Methotrexate 52Cytarabine 51fludarabine 49Melphalan 48Busulfan 47Tacrolimus 41Whole-Body Irradiation 39Mycophenolic Acid 39Granulocyte Colony-Stimulating Factor 37Antilymphocyte Serum 31Peripheral Blood Stem Cell Transplantation 30Radiotherapy 27Lenalidomide 25Dexamethasone 25Carmustine 23Stem Cell Transplantation 22Cyclosporine 22Bortezomib 22Gemcitabine 20Bendamustine Hydrochloride 20ibritumomab tiuxetan 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma × AP 1903 reagent × Clear all
NCT01875237 2019-07-16

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡